Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Receivables (2021 - 2025)

Historic Receivables for Keros Therapeutics (KROS) over the last 4 years, with Q3 2025 value amounting to $3.5 million.

  • Keros Therapeutics' Receivables rose 80000.0% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 80000.0%. This contributed to the annual value of $2.7 million for FY2024, which is 181748.25% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Receivables is $3.5 million, which was up 80000.0% from $15.8 million recorded in Q2 2025.
  • Keros Therapeutics' Receivables' 5-year high stood at $18.0 million during Q4 2021, with a 5-year trough of $4000.0 in Q2 2024.
  • For the 4-year period, Keros Therapeutics' Receivables averaged around $5.8 million, with its median value being $1.6 million (2024).
  • Within the past 5 years, the most significant YoY rise in Keros Therapeutics' Receivables was 39530000.0% (2025), while the steepest drop was 80000.0% (2025).
  • Over the past 4 years, Keros Therapeutics' Receivables (Quarter) stood at $18.0 million in 2021, then crashed by 99.21% to $143000.0 in 2023, then skyrocketed by 1817.48% to $2.7 million in 2024, then rose by 27.35% to $3.5 million in 2025.
  • Its Receivables stands at $3.5 million for Q3 2025, versus $15.8 million for Q2 2025 and $17.3 million for Q1 2025.